Broad's David Altshuler tapped as new CSO at Vertex

David Altshuler

A little more than four years ago Thomson Reuters selected David Altshuler, the deputy director and chief academic officer of the legendary Broad Institute, as one of the world's "hottest" researchers. And today Vertex ($VRTX) announced that he'll be bringing the heat to the Boston biotech as its new CSO, taking the place of the pioneering Peter Mueller. Altshuler comes into his new position with an insider's perspective. He was named to the board back in 2012, when the biotech was making a huge shift from hepatitis C to cystic fibrosis, where it's been a pioneering force. "During my time on the board of directors, I have been tremendously impressed by Vertex's ability to integrate fundamental disease biology and cutting edge technology to help patients and to maintain a commitment to scientific excellence through a period of significant global growth," the scientist said in a statement. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.